United Therapeutics Corp (UTHR) Easily Beats Q3 Views; Revs Top $200M
United Therapeutics Corp (NASDAQ: UTHR) reported Q3 EPS of $1.65, $0.92 better than the analyst estimate of $0.73. Revenue for the quarter came in at $201.7 million versus the consensus estimate of $194.77 million.
